Literature DB >> 11413321

Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase.

J G Julias1, A L Ferris, P L Boyer, S H Hughes.   

Abstract

The amount of excess polymerase and RNase H activity in human immunodeficiency virus type 1 virions was measured by using vectors that undergo a single round of replication. Vectors containing wild-type reverse transcriptase (RT), vectors encoding the D110E mutation to inactivate polymerase, and vectors encoding mutations D443A and E478Q to inactivate RNase H were constructed. 293 cells were cotransfected with different proportions of plasmids encoding these vectors to generate phenotypically mixed virions. The resulting viruses were used to infect human osteosarcoma cells, and the relative infectivity of the viruses was determined by measuring transduction of the murine cell surface marker CD24, which is encoded by the vectors. The results indicated that there is an excess of both polymerase and RNase H activities in virions. Viral replication was reduced to 42% of wild-type levels in virions with where half of the RT molecules were predicted to be catalytically active but dropped to 3% of wild-type levels when 25% of the RT molecules were active. However, reducing RNase H activity had a lesser effect on viral replication. As expected, based on previous work with murine leukemia virus, there was relatively inefficient virus replication when the RNase H and polymerase activities were encoded on separate vectors (D110E plus E478Q and D110E plus D443A). To determine how virus replication failed when polymerase and RNase H activities were reduced, reverse transcription intermediates were measured in vector-infected cells by using quantitative real-time PCR. The results indicated that using the D11OE mutation to reduce the amount of active polymerase reduced the number of reverse transcripts that were initiated and also reduced the amounts of products from the late stages of reverse transcription. If the E478Q mutation was used to reduce RNase H activity, the number of reverse transcripts that were initiated was reduced; there was also a strong effect on minus-strand transfer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413321      PMCID: PMC114377          DOI: 10.1128/JVI.75.14.6537-6546.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Effects on DNA synthesis and translocation caused by mutations in the RNase H domain of Moloney murine leukemia virus reverse transcriptase.

Authors:  S W Blain; S P Goff
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.

Authors:  J He; S Choe; R Walker; P Di Marzio; D O Morgan; N R Landau
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 3.  Generation of high-titer pseudotyped retroviral vectors with very broad host range.

Authors:  J K Yee; T Friedmann; J C Burns
Journal:  Methods Cell Biol       Date:  1994       Impact factor: 1.441

4.  Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity.

Authors:  M Tisdale; T Schulze; B A Larder; K Moelling
Journal:  J Gen Virol       Date:  1991-01       Impact factor: 3.891

5.  Interaction of HIV-1 ribonuclease H with polypurine tract containing RNA-DNA hybrids.

Authors:  B M Wöhrl; K Moelling
Journal:  Biochemistry       Date:  1990-11-06       Impact factor: 3.162

6.  Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.

Authors:  K J Livak; S J Flood; J Marmaro; W Giusti; K Deetz
Journal:  PCR Methods Appl       Date:  1995-06

7.  Defects in primer-template binding, processive DNA synthesis, and RNase H activity associated with chimeric reverse transcriptases having the murine leukemia virus polymerase domain joined to Escherichia coli RNase H.

Authors:  J Guo; W Wu; Z Y Yuan; K Post; R J Crouch; J G Levin
Journal:  Biochemistry       Date:  1995-04-18       Impact factor: 3.162

8.  Construction of an enzymatically active ribonuclease H domain of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  S J Stahl; J D Kaufman; S Vikić-Topić; R J Crouch; P T Wingfield
Journal:  Protein Eng       Date:  1994-09

9.  Substitution of a highly basic helix/loop sequence into the RNase H domain of human immunodeficiency virus reverse transcriptase restores its Mn(2+)-dependent RNase H activity.

Authors:  J L Keck; S Marqusee
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.

Authors:  R I Connor; B K Chen; S Choe; N R Landau
Journal:  Virology       Date:  1995-02-01       Impact factor: 3.616

View more
  77 in total

1.  RNase H activity is required for high-frequency repeat deletion during Moloney murine leukemia virus replication.

Authors:  Jennifer L Brincat; Julie K Pfeiffer; Alice Telesnitsky
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo.

Authors:  John G Julias; Mary Jane McWilliams; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

3.  Effects of mutations in the G tract of the human immunodeficiency virus type 1 polypurine tract on virus replication and RNase H cleavage.

Authors:  John G Julias; Mary Jane McWilliams; Stefan G Sarafianos; W Gregory Alvord; Eddy Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  HIV-1 capsid-targeting domain of cleavage and polyadenylation specificity factor 6.

Authors:  Kyeongeun Lee; Alok Mulky; Wendy Yuen; Thomas D Martin; Nicholas R Meyerson; Laura Choi; Hyun Yu; Sara L Sawyer; Vineet N Kewalramani
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

5.  Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.

Authors:  Jiong Wang; Robert A Bambara; Lisa M Demeter; Carrie Dykes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

6.  Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.

Authors:  Jiong Wang; Gang Zhang; Robert A Bambara; Dongge Li; Hua Liang; Hulin Wu; Hannah M Smith; Nicholas R Lowe; Lisa M Demeter; Carrie Dykes
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

7.  Hydrolysis of RNA/DNA hybrids containing nonpolar pyrimidine isosteres defines regions essential for HIV type 1 polypurine tract selection.

Authors:  Jason W Rausch; Jin Qu; Hye Young Yi-Brunozzi; Eric T Kool; Stuart F J Le Grice
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-12       Impact factor: 11.205

8.  Mutations in the 5' end of the human immunodeficiency virus type 1 polypurine tract affect RNase H cleavage specificity and virus titer.

Authors:  Mary Jane McWilliams; John G Julias; Stefan G Sarafianos; W Gregory Alvord; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Mutations in the U5 region adjacent to the primer binding site affect tRNA cleavage by human immunodeficiency virus type 1 reverse transcriptase in vivo.

Authors:  Jangsuk Oh; Mary Jane McWilliams; John G Julias; Stephen H Hughes
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

10.  Mutations in human immunodeficiency virus type 1 nucleocapsid protein zinc fingers cause premature reverse transcription.

Authors:  James A Thomas; William J Bosche; Teresa L Shatzer; Donald G Johnson; Robert J Gorelick
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.